CASI Pharma Gains Hong Kong OK for Cancer Drug

CASI Pharma, a US biopharma focused on the China market, reported that Zevalin®, a treatment for non-Hodgkin's lymphoma, is now available in Hong Kong. One year ago, CASI in-licensed three cancer drugs from Spectrum Pharma, and this represents the first marketing approval for any of the three. To acquire the China rights, CASI granted Spectrum a 20% stake in CASI and a promissory note for $1.5 million. ChinaBio® Today estimated the value of the package at $11.5 million. More details.... Stock Symbols: (NSDQ: CASI) (NSDQ: SPPI ) Share this with colleagues: // //